" class="no-js "lang="en-US"> Vig Chandramouli - Medtech Alert
Wednesday, December 04, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Vig Chandramouli

Vig Chandramouli

About Vig Chandramouli

Vignesh Chandramouli (HC), a Partner at Oak HC/FT, joined the firm in 2014 and focuses on growth equity and early-stage venture opportunities in Healthcare.

Vig currently serves on the Board of Osso VR and Syllable and is a Board Observer at Advise, CareBridge, OncoHealth, Reveleer, Unite US, Veda, Vesta Healthcare, and VillageMD. Vig is also actively involved with Main Street Health, Notable, Quartet, Rialtic, Unified and Wayspring. Recent prior investments include Aspire Health (acquired by Anthem), Core Informatics (acquired by Thermo Fisher Scientific), LDI Integrated Pharmacy Services (acquired by Diplomat Pharmacy), Maestro Health (acquired by AXA Group), and Therapy Brands (acquired by KKR).

Prior to joining Oak HC/FT, Vig was an Associate with LLR Partners, a middle-market growth equity firm, where he focused on investments in healthcare services companies.

Vig received a dual Bachelor of Science degree, magna cum laude, from the University of Pennsylvania’s Wharton School and the School of Engineering and Applied Science.

Related Story

Fundraising

 Osso VR Raises $66 Million to Broaden Access to Surgical Education for Healthcare Professionals | Pharmtech Focus

Osso VR Raises $66 Million to Broaden Access to Surgical Education for Healthcare Professionals

March 25 2022

Osso VR, a validated virtual reality (VR) surgical training and assessment platform, today announced that […]